Highly cited articles and current hotspots
Studies with high co-citation counts often represent fundamental and
fundamental research in the field and are generally published earlier.
Except for the EPOS, we summarized the nine most co-cited articles,
which can be divided into three categories: immune features and
endotypes, clinical applications, and epidemiological analyses. Of these
nine articles, 6 explored the inflammatory patterns in CRS in different
countries or different endotypes, and they collectively focused on the
cell expression profile and immune marker profile of CRS patients, such
as T(H)1/ T(H)2 skewed inflammation [21-23,44-46].
In addition, two publications focused on clinical applications,
respectively evaluating the effectiveness of SNOT-22 (a derivative of
SNOT-20), a quality-of-life questionnaire for patients with CRS[47], and the clinical efficacy of Omalizumab[48]. Moreover, the last publication was the
European international multicentre prevalence study of CRS[49]. It should be noted, however, that the value
of an article is not reliably measured by co-citation alone, as the
newly published articles will rank lower when analyzed in terms of
citations independently. In contrast, many incoming articles have
significantly impacted frontier research.
By analyzing the timing and frequency of keyword appearances, we could
obtain the current frontier research about CRS and NPs. Subsequently, we
grouped the current frontier research hotspots into three sections:
monoclonal antibodies and biologics, Covid-19, Inflammatory response,
and endotypes.